Literature DB >> 35646824

Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools.

Isabelle Landrieu1,2, Elian Dupré1,2, Davy Sinnaeve1,2, Léa El Hajjar1,2, Caroline Smet-Nocca1,2.   

Abstract

Protein aggregation into highly ordered, regularly repeated cross-β sheet structures called amyloid fibrils is closely associated to human disorders such as neurodegenerative diseases including Alzheimer's and Parkinson's diseases, or systemic diseases like type II diabetes. Yet, in some cases, such as the HET-s prion, amyloids have biological functions. High-resolution structures of amyloids fibrils from cryo-electron microscopy have very recently highlighted their ultrastructural organization and polymorphisms. However, the molecular mechanisms and the role of co-factors (posttranslational modifications, non-proteinaceous components and other proteins) acting on the fibril formation are still poorly understood. Whether amyloid fibrils play a toxic or protective role in the pathogenesis of neurodegenerative diseases remains to be elucidated. Furthermore, such aberrant protein-protein interactions challenge the search of small-molecule drugs or immunotherapy approaches targeting amyloid formation. In this review, we describe how chemical biology tools contribute to new insights on the mode of action of amyloidogenic proteins and peptides, defining their structural signature and aggregation pathways by capturing their molecular details and conformational heterogeneity. Challenging the imagination of scientists, this constantly expanding field provides crucial tools to unravel mechanistic detail of amyloid formation such as semisynthetic proteins and small-molecule sensors of conformational changes and/or aggregation. Protein engineering methods and bioorthogonal chemistry for the introduction of protein chemical modifications are additional fruitful strategies to tackle the challenge of understanding amyloid formation.
Copyright © 2022 Landrieu, Dupré, Sinnaeve, El Hajjar and Smet-Nocca.

Entities:  

Keywords:  aggregation; amyloid fibril; fluorescent probes; nanobody; native chemical ligation; neurodegenerative diseases; posttranslational modifications; protein semisynthesis

Year:  2022        PMID: 35646824      PMCID: PMC9133342          DOI: 10.3389/fchem.2022.886382

Source DB:  PubMed          Journal:  Front Chem        ISSN: 2296-2646            Impact factor:   5.545


  378 in total

1.  Conformations of microtubule-associated protein Tau mapped by fluorescence resonance energy transfer.

Authors:  Sadasivam Jeganathan; Subashchandrabose Chinnathambi; Eva-Maria Mandelkow; Eckhard Mandelkow
Journal:  Methods Mol Biol       Date:  2012

2.  A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation.

Authors:  Avinash Patel; Hyun O Lee; Louise Jawerth; Shovamayee Maharana; Marcus Jahnel; Marco Y Hein; Stoyno Stoynov; Julia Mahamid; Shambaditya Saha; Titus M Franzmann; Andrej Pozniakovski; Ina Poser; Nicola Maghelli; Loic A Royer; Martin Weigert; Eugene W Myers; Stephan Grill; David Drechsel; Anthony A Hyman; Simon Alberti
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

3.  The binding of thioflavin-T to amyloid fibrils: localisation and implications.

Authors:  M R H Krebs; E H C Bromley; A M Donald
Journal:  J Struct Biol       Date:  2005-01       Impact factor: 2.867

4.  Regulation of Pin1 peptidyl-prolyl cis/trans isomerase activity by its WW binding module on a multi-phosphorylated peptide of Tau protein.

Authors:  Caroline Smet; Jean-Michel Wieruszeski; Luc Buée; Isabelle Landrieu; Guy Lippens
Journal:  FEBS Lett       Date:  2005-08-01       Impact factor: 4.124

5.  Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides.

Authors:  Georg Meisl; Xiaoting Yang; Erik Hellstrand; Birgitta Frohm; Julius B Kirkegaard; Samuel I A Cohen; Christopher M Dobson; Sara Linse; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-17       Impact factor: 11.205

6.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.

Authors:  Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Gerald W Hart; Cheng-Xin Gong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

7.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.

Authors:  A Abraha; N Ghoshal; T C Gamblin; V Cryns; R W Berry; J Kuret; L I Binder
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

Review 8.  O-GlcNAcylation in health and neurodegenerative diseases.

Authors:  Byeong Eun Lee; Pann-Ghill Suh; Jae-Ick Kim
Journal:  Exp Mol Med       Date:  2021-11-26       Impact factor: 8.718

9.  Exploring the role of post-translational modifications in regulating α-synuclein interactions by studying the effects of phosphorylation on nanobody binding.

Authors:  Farah El Turk; Erwin De Genst; Tim Guilliams; Bruno Fauvet; Mirva Hejjaoui; Justin Di Trani; Anass Chiki; Anthony Mittermaier; Michele Vendruscolo; Hilal A Lashuel; Christopher M Dobson
Journal:  Protein Sci       Date:  2018-07       Impact factor: 6.725

Review 10.  Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.

Authors:  Ruiqing Ni; Roger M Nitsch
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.